Solution
Industries
Resources
About
Beacon Search

NeoGenomics Laboratories

Company Snapshot

Founded: 2002
Entity Type: Public
Employees: 2,200
Region: U.S.
Revenue: $660.6 Millions
Revenue Year: 2024
Headquarter: Florida, U.S.
Key Geographics: U.S.
Corporate Address: 9490 NeoGenomics Way Fort Myers, Florida 33912 U.S. Tel. +1-239-768-0600 www.neogenomics.com

Company Overview

NeoGenomics is a leading provider of cancer diagnostic, pharmaceutical, and information services that aid oncologists, pathologists, pharmaceutical firms, and academic institutions in their mission to improve the lives of cancer patients. With a focus on cancer, NeoGenomics Laboratories has been providing lab diagnostics and clinical trial services to patients for more than 18 years. NeoGenomics team includes a global network of medical experts, researchers, and lab technicians that collaborate with cancer care teams to provide essential oncology solutions that will improve the quality of life for cancer patients. The company’s clinical diagnostic services enable a personalized testing strategy by offering customized and targeted diagnostics to match patient’s needs. Its extensive portfolio includes both conventional and cutting-edge testing. The firm’s customer base includes academic institutions, hospitals, private pathology laboratories, contract research organizations, office-based oncologists, and pharmaceutical companies, among others.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

NeoGenomics Laboratories In Reports

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

BCC Research Report: Dive into Liquid Biopsy Research market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a CAGR projection.

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Discover BCC Research's report on Next-generation Sequencing Market is steadily being integrated into clinical laboratory analysis, testing, and disease diagnostics in healthcare sectors globally.

Minimal Residual Disease Testing: Global Markets and Technologies

BCC Research Market Report says global market for minimal residual disease testing is estimated to increase from $2.2 billion in 2023 to reach $4.3 billion by 2028.

View All Reports

Company's Business Segments

  • Clinical Services : Clinical cancer testing, Interpretation and consultative services, Molecular and NGS testing, Comprehensive technical and professional services offering

Applications/End User Industries

  • Pharmaceuticals
  • Genetic Testing
  • Molecular Testing
  • Healthcare
  • Life Sciences
  • Clinical Pathology Testing
  • Anatomic Pathology Testing
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.
Contact
© 2025 BCC Research
Privacy Policy |Site Map|Terms & Conditions